S1 Biopharma Granted Patents for Lorexys™ in Europe and Asia for Treatment of Hypoactive Sexual Desire Disorder

Newest patents significantly strengthen S1 intellectual property position

S1 Biopharma, Inc. (S1) announced today that the European Patent Office has granted a European Patent for the Company’s proprietary dual-mechanistic therapy Lorexys for hypoactive sexual desire disorder. A corresponding patent was previously granted in several countries in Asia including ChinaJapanSouth Korea, and Singapore.

Image source – http://s1biopharma.com

The EU patent, entitled Composition for Treating Hypoactive Sexual Desire Disorder (#2694065), will provide an exclusivity period until 2032.

“We are pleased that the European Patent Office has granted this patent for Lorexys, which has the clear potential to offer a unique and innovative treatment for hypoactive sexual desire disorder,” stated Nicolas G. Sitchon, Chief Executive Officer of S1. He added, “This most recent patent together with those previously granted in Asia significantly strengthen and extend our intellectual property estate for Lorexys.”

The Company has filed corresponding patent applications in other countries around the world.

About S1 Biopharma, Inc.
S1 Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the treatment of sexual dysfunction in both women and men. The company’s development programs include first-in-class non-hormonal therapies designed to treat diminished sexual desire by restoring the natural balance of key neurotransmitters in the brain. The company’s lead product candidate, Lorexys, is currently positioned to advance to a Phase 2b clinical trial for the treatment of hypoactive sexual desire disorder (HSDD) in women. S1 Biopharma is evaluating partnerships, collaborations and out-licensing deals that will enable the company to rapidly advance its sexual dysfunction franchise as well as to accelerate the path to commercialization for its drug candidates in the U.S. and internationally. For more information, visit http://s1biopharma.com/ or follow S1 Biopharma on Facebook or Twitter (@s1biopharma).

SOURCE S1 Biopharma, Inc.

Related Links


You Might Also Like